A Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK-8150 (MK-8150-002)
PHASE1CompletedINTERVENTIONAL
Enrollment
103
Participants
Timeline
Start Date
August 1, 2012
Primary Completion Date
May 3, 2013
Study Completion Date
May 23, 2013
Conditions
HypertensionIsolated Systolic Hypertension
Interventions
DRUG
MK-8150
DRUG
Placebo for MK-8150
All Listed Sponsors
lead
Merck Sharp & Dohme LLC
INDUSTRY
NCT01656408 - A Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK-8150 (MK-8150-002) | Biotech Hunter | Biotech Hunter